FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct'- Science
Brief: Cassava Sciences Completes Patient Enrollment For Pivotal Phase 3 Trial Of Oral Simufilam In Alzheimer's Disease
Incyte slides as GSK's bone marrow cancer therapy gets FDA nod
Cassava Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cassava Sciences Reports Q2 2023 Financial Results And Operating Updates
Brief: Cassava Sciences Q2 Basic EPS USD -0.63
Cassava Sciences Inc expected to post a loss of 59 cents a share - Earnings Preview
Cassava Sciences down as Alzheimer's disease drug study fails to impress
Brief: Oral Simufilam Slowed Cognitive Decline In A Randomized Withdrawal Trial Of Mild-To-Moderate Alzheimer's Disease
Live Markets: Digimarc among top 'squeeze' targets -S3 Partners
Cassava up after dosing completed in controlled Alzheimer's drug trial
Brief: Cassava Sciences Completes Patient Dosing In A Randomized Controlled Trial Of Simufilam In Alzheimer’S Disease
Cassava Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cassava Sciences Enters Into Sales Agreement
Brief: Cassava Sciences Reports Q1 2023 Financial Results And Operating Updates
Brief: Cassava Sciences posts Q1 EPS USD -0.58
Cassava Sciences Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Cassava Sciences Inc Has No Financial Exposure To Silicon Valley Bank Or Silvergate Bank
Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary